Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse

This article was originally published in The Pink Sheet Daily

Executive Summary

The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.

You may also be interested in...



Brand And Generic Opioid Makers Agree: FDA Should Issue Guidance On Tamper Resistance

But Purdue and Teva disagree on the key question of whether a generic of a tamper-resistant analgesic must have the same dosage form as the reference-listed brand-name drug.

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Related Content

Topics

UsernamePublicRestriction

Register

PS070529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel